Show simple item record

dc.contributor.authorBeyan, C
dc.contributor.authorArslan, O
dc.contributor.authorOzcan, M
dc.contributor.authorGurman, G
dc.contributor.authorIlhan, O
dc.contributor.authorAkan, H
dc.contributor.authorKalayoglu-Besisik, Sevgi
dc.contributor.authorBeksac, M
dc.contributor.authorCelebi, H
dc.contributor.authorSargin, D
dc.contributor.authorYalcin, A
dc.contributor.authorTopcuoglu, P
dc.date.accessioned2021-03-04T18:01:43Z
dc.date.available2021-03-04T18:01:43Z
dc.date.issued2003
dc.identifier.citationBeksac M., Celebi H., Sargin D., Yalcin A., Topcuoglu P., Kalayoglu-Besisik S., Beyan C., Arslan O., Ozcan M., Gurman G., et al., "Role of pretransplant interferon-α(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): Results from three Turkish transplant centers", Bone Marrow Transplantation, cilt.31, ss.897-904, 2003
dc.identifier.issn0268-3369
dc.identifier.otherav_8895b938-3655-4034-840d-8a5875a48e98
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/92670
dc.identifier.urihttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=0038621693&origin=inward
dc.identifier.urihttps://doi.org/10.1038/sj.bmt.1703930
dc.description.abstractSince transplantation cannot be performed immediately after the diagnosis of chronic myelogenous leukemia (CML), interferon treatment is usually required. This study aims to analyze the effects of interferon-alpha (IFN) treatment on allogeneic stem cell transplantation (SCT) outcome. A total of 106 patients aged 16-47 years and transplanted from HLA-identical sibling donors for CML in chronic phase (CP) were evaluated. In all, 48 had received IFN-alpha for a median duration of 5 months (1-18 months) until a median of 1 month prior to transplantation. Of the patients, 50 have received bone marrow transplant (BMT) whereas 56 have received peripheral blood stem cells (PBSCT) between 1991 and 1999 in three major transplant centers in Turkey. Patient characteristics in both groups were similar. More hematological responders were present in the IFN(+) patients (P = 0.0001). No difference was found in engraftment kinetics. The incidences of acute or chronic graft-versus-host disease (GVHD), relapse and graft failure were similar in all patients regardless of stem cell source. Overall survival (OS) and disease-free survival (DFS) at 2 years were similar for both IFN(+) or (-) patients following SCT. With multivariate analysis, pretransplant IFN-alpha use, stem cell source, transplant year and CD34+ cell content were not found to be risk factors for OS. In conclusion, prior IFN exposure did not impair BMT or PBSCT outcome.
dc.language.isoeng
dc.subjectHematoloji
dc.subjectBİYOFİZİK
dc.subjectBiyoloji ve Biyokimya
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectONKOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectHEMATOLOJİ
dc.subjectİmmünoloji
dc.subjectTRANSPLANTASYON
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectTemel Tıp Bilimleri
dc.subjectBiyofizik
dc.subjectBiyokimya
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.titleRole of pretransplant interferon-α(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): Results from three Turkish transplant centers
dc.typeMakale
dc.relation.journalBone Marrow Transplantation
dc.contributor.department, ,
dc.identifier.volume31
dc.identifier.issue10
dc.identifier.startpage897
dc.identifier.endpage904
dc.contributor.firstauthorID168386


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record